Emerging Biologic and Clinical Implications of Mir-182-5P in Gynecologic Cancers Publisher

Summary: miR-182-5p may drive gynecologic cancers, study suggests, showing promise as a biomarker and therapy target. #WomensCancer #MicroRNA

Zehtabi M¹ ; Ghaedrahmati F² ; Dari MAG³ ; Moramezi F⁴ ; Kempisty B^{5, 6, 7, 8} ; Mozdziak P⁷ ; Farzaneh M^{4, 9}
Source: Clinical and Translational Oncology Published:2024

Abstract

MicroRNAs (miRNAs) have emerged as important regulators of gene expression in various biological processes, including cancer. miR-182-5p has gained attention for its potential implications in gynecologic cancers, including breast, ovarian, endometrial, and cervical cancers. miR-182-5p dysregulation has been associated with multiple facets of tumor biology in gynecologic cancers, including tumor initiation, progression, metastasis, and therapeutic response. Studies have highlighted its involvement in key signaling pathways and cellular processes that contribute to cancer development and progression. In addition, miR-182-5p has shown potential as a diagnostic and prognostic biomarker, with studies demonstrating its correlation with clinicopathological features and patient outcomes. Furthermore, the therapeutic potential of miR-182-5p is being explored in gynecologic cancers. Strategies such as miRNA mimics or inhibitors targeting miR-182-5p have shown promise in preclinical and early clinical studies. These approaches aim to modulate miR-182-5p expression, restoring normal cellular functions and potentially enhancing treatment responses. Understanding the biologic and clinical implications of miR-182-5p in gynecologic cancers is crucial for the development of targeted therapeutic strategies and personalized medicine approaches. Further investigations are needed to unravel the specific target genes and pathways regulated by miR-182-5p. It is important to consider the emerging biologic and clinical implications of miR-182-5p in gynecologic cancers. © The Author(s), under exclusive licence to Federacion de Sociedades Espanolas de Oncologia (FESEO) 2024.